MedPath

Meditation-Relaxation (MR Therapy) for Sleep Paralysis.

Not Applicable
Conditions
Narcolepsy Type 1
Sleep Paralysis
Interventions
Behavioral: MR therapy.
Behavioral: breathing-distraction exercise
Registration Number
NCT04483310
Lead Sponsor
Azienda Usl di Bologna
Brief Summary

The aim of the study is to evaluate, with a small-scale pilot study, the efficacy of Meditation Relaxation therapy for Sleep Paralyses in patients with narcolepsy. The study involves two arms, with intervention with Meditation Relaxation therapy or sham over a period of three months.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
20
Inclusion Criteria
  • Narcolepsy (type 1 and 2) based on polysomnography, Multiple Sleep Latency Test [MLST] and CSF hypocretin level testing).
  • Patients had to have experienced SP at least four times in the last month.
Read More
Exclusion Criteria
  • Psychiatric comorbidity.
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
MR therapyMR therapy.MR therapy is a psychological treatment for SP, comprised of the following steps applied directly during the attack: Step I: Reappraisal of the meaning of the attack; Step II: psychological and emotional distancing; Step III: inward focused-attention meditation; Step IV: Muscle relaxation.
Control interventionbreathing-distraction exerciseThe control intervention was identical, except participants engaged in deep breathing; entailing slow deep breaths, while repeatedly counting from 1-10. This is an active control (breathing-distraction exercise) rather than a placebo.
Primary Outcome Measures
NameTimeMethod
Sleep Paralysis Experiences and Phenomenology Questionnaire (SP-EPQ)Three months.

The questionnaire addresses the distress associated with SP.

Secondary Outcome Measures
NameTimeMethod
Daily journalThree months.

Each day during the study (12 weeks), participants rated their SP occurrence, perceived duration (sec./min.), fear associated with SP, and disturbance caused by hallucinations (on a ten-point scale).

Trial Locations

Locations (1)

Azienda USL di Bologna

🇮🇹

Bologna, Italy

© Copyright 2025. All Rights Reserved by MedPath